Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis

Emerg Infect Dis. 2017 Oct;23(10):1718-1721. doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.

Abstract

We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency. For 2 patients, QT-interval prolongation but no arrhythmias occurred. Use of this therapy is justified for patients with limited options.

Keywords: Europe; India; Italy; MDR TB; Mycobacterium tuberculosis; Russia; Switzerland; TB; United Kingdom; XDR TB; antimicrobial resistance; bacteria; bedaquiline; combination treatment; delamanid; effectiveness; multidrug resistance; multidrug-resistant tuberculosis; mycobacteria; pulmonary; respiratory infections; safety; the Netherlands; tolerability; tuberculosis.

MeSH terms

  • Adolescent
  • Adult
  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / therapeutic use*
  • Diarylquinolines / administration & dosage
  • Diarylquinolines / therapeutic use*
  • Drug Therapy, Combination
  • Extensively Drug-Resistant Tuberculosis / drug therapy*
  • Female
  • Humans
  • Male
  • Nitroimidazoles / administration & dosage
  • Nitroimidazoles / therapeutic use*
  • Oxazoles / administration & dosage
  • Oxazoles / therapeutic use*
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / microbiology
  • Young Adult

Substances

  • Antitubercular Agents
  • Diarylquinolines
  • Nitroimidazoles
  • OPC-67683
  • Oxazoles
  • bedaquiline